Semaglutide: Did weight, heart, and kidney problems change?

What is the short answer about semaglutide?

Scientists changed a meal hormone to make the resulting drug remain active longer. Semaglutide copies GLP-1, a meal hormone involved in controlling the sugar in blood.

The large studies didn't test every possible benefit in the same people. Studies found weight loss and lower totals of serious heart or kidney-related problems in those patients ^[9][10][11].

STEP 1 studied adults carrying excess weight but excluded people who had diabetes ^[11]. Obesity means enough excess body fat to raise the risk of health problems.

SELECT required excess weight alongside existing heart disease, and patients with diabetes couldn't enter ^[10]. Those starting health problems matter when you ask whether the heart finding applies to you.

FLOW studied people with type 2 diabetes alongside kidney disease that hadn't gone away ^[9]. That test gives you one total covering deaths as well as serious kidney problems.

Stomach and bowel side effects, especially nausea, made treatment difficult for some people ^[12]. Gallbladder problems and unanswered questions about rare harms also affect how you judge the benefit.

What helps semaglutide stay in the blood longer?

Semaglutide has a 31-amino-acid chain, built from small parts called amino acids that also occur in proteins. The drug resembles glucagon-like peptide-1, or GLP-1, a hormone the body sends out after eating.

Scientists changed parts so enzymes, proteins that help break substances down, remove the drug more slowly. The slower breakdown lets the drug keep acting after a natural meal hormone would fade.

Scientists attached a little fat during manufacture to help the drug stay active longer. The added fat helps the drug hold onto a blood protein, slowing its removal further.

Your blood holding a drug longer doesn't prove which illnesses the medicine can help. Each form of treatment still needs a study in the people concerned.

People's illnesses and their other care affect what a new treatment has to improve. A bottle carrying the drug name doesn't necessarily have the contents studied in those patients.

An approved drug has checks on its contents, strength, and cleanliness during manufacture. You can't assume those studies or checks cover uncertain material described as being for research.

Why can semaglutide lower blood sugar and leave you fuller?

Semaglutide copies GLP-1, a hormone that helps with sugar control following food. When sugar in your blood rises, the pancreas gland beside the stomach releases more insulin.

The hormone insulin lets your cells take sugar from the blood and use the sugar. Semaglutide also reduces glucagon, a hormone that tells the body to release more sugar.

Semaglutide keeps food in your stomach longer and changes how the brain controls hunger. Fullness may arrive sooner, helping you eat less while also sometimes causing nausea.

These effects don't by themselves prove that heart attacks or kidney failure become less common. Separate studies checked those serious health problems in those study patients ^[9][10].

Your health before treatment and the other medicines you take can affect the benefit. What care and medicines you can get also affects the result for your health.

For your health, ask what happened to patients alongside asking how the drug acts. Approved uses and warnings concern the particular form of treatment that was assessed.

How much weight changed, and what happened to health?

STEP 1 used chance to decide who received each treatment among 1,961 adults carrying excess weight without having diabetes, giving you a fairer comparison of changes in weight during the study. At 68 weeks, weight fell on average by 14.9% with semaglutide and 2.4% with placebo, treatment without active drug ^[11].

You get an answer about weight during the time researchers followed those patients. Weight loss alone doesn't prove how much longer anyone will live after treatment.

SELECT involved 17,604 adults carrying excess weight who had heart disease and didn't have diabetes. Semaglutide reduced the total count of fatal heart problems, nonfatal heart attacks, and nonfatal strokes against placebo ^[10].

FLOW involved 3,533 people whose type 2 diabetes came with kidney disease that persisted. Serious kidney problems and kidney- or heart-related deaths were less common with semaglutide when counted together ^[9].

You need to know that the total included kidney failure and serious loss of blood filtering. The lower total doesn't by itself tell you how much each separate problem changed.

SURMOUNT-5 assigned 751 adults with obesity to semaglutide or tirzepatide by chance. At 72 weeks, weight fell on average by 20.2% with tirzepatide and 13.7% with semaglutide ^[8].

That comparison favored tirzepatide for weight, without answering every other question about health. A type 2 diabetes review judged semaglutide's benefits generally greater than its risks, including stomach, bowel, and gallbladder problems ^[12].

Pancreas illness and thyroid cancer were too uncommon in the reviewed studies to settle those concerns. The thyroid is the gland in your neck; scarce evidence can't prove that treatment is safe.

What complaints came from research users and from studies?

These are research users' personal accounts; fair studies haven't checked that the drug caused these experiences. People describe earlier fullness, fewer food cravings, less thinking about food, weight loss, and steadier blood sugar.

Reports include nausea, constipation, diarrhea, tiredness, unusual burps, and foods people no longer want. Reflux also appears in reports; stomach contents come back up and can cause burning.

You may also read accounts of headaches, sore shot sites, less interest in alcohol, or hair shedding. Those accounts leave you uncertain about how frequently people have problems or what caused them.

Published studies more clearly show stomach and bowel complaints causing some people to stop treatment ^[12]. Researchers reviewing the studies also found more gallbladder problems, including concern about stones there ^[12].

The same review left questions about pancreas illness and cancer of the thyroid gland unsettled ^[12]. The review couldn't prove a link, but couldn't rule out that link either.

If blood sugar falls quickly, diabetes damage already present inside the eye can worsen ^[12]. The concern is the light-sensitive lining at the back, in people who already have that damage.

Large weight loss also leaves questions about losing muscle and regaining weight after treatment stops. The papers don't support giving you exact estimates for those wider concerns here.

Studies of checked prescription drugs can't tell you the strength or contents of uncertain research material. Your treatment questions need medical assessment; these findings don't tell you how to use the drug.

Why might your health differ from the study patients’ health?

Separate semaglutide studies examined kidney disease, heart problems, and weight in different groups of people. Each study tested its own health question, rather than checking all benefits at once ^[9][10][11].

You get more useful answers from those separate tests than from weight loss alone. A claim about the heart or kidneys needs evidence from patients with those problems.

People enter a study with different chances of getting ill or recovering from illness. Their starting health and usual care affect how much an added treatment can help.

Your possible benefit may be smaller if you're healthier than the patients who entered each test. Approved uses can also differ across countries and between forms of the medicine.

Tirzepatide copies two meal hormones, while semaglutide copies the action of one. SURMOUNT-5 favored tirzepatide for weight loss, but that study doesn't settle every other health question ^[8].

Thymosin alpha-1 and PT-141 studies addressed very different problems from excess weight. The four-medicine comparison keeps those findings tied to the patients and illnesses actually studied.